Volume 95 Issue 36 | p. 13 | Concentrates
Issue Date: September 11, 2017

Chinese firm acquires Canadian contractor

Department: Business
Keywords: Outsourcing, Biologics, China, Canada

The Chinese biopharmaceutical firm 3SBio has agreed to buy Therapure Biomanufacturing, a biologics contract manufacturer, for $290 million. Based outside Toronto, Therapure employs about 340 people in North America. 3SBio says the acquisition will add North American purification and plasma source technologies to its Chinese mammalian cell culture capabilities. In 2014, 3SBio acquired Sirton, an Italian contract manufacturer of injectable drugs. Based in Shenyang, northern China, 3SBio produces biotech and chemical drugs for its own . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society